Your browser doesn't support javascript.
loading
Phase 2 study of anastrozole in rare cohorts of patients with estrogen receptor/progesterone receptor positive leiomyosarcomas and carcinosarcomas of the uterine corpus: The PARAGON trial (ANZGOG 0903).
Edmondson, R J; O'Connell, R L; Banerjee, S; Mileshkin, L; Sykes, P; Beale, P; Fisher, A; Bonaventura, A; Millan, D; Nottley, S; Benson, C; Hamilton, A; Sjoquist, K; Alexander, L; Kelly, C; Carty, K; Divers, L; Bradshaw, N; Friedlander, M.
Afiliación
  • Edmondson RJ; Division of Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester, St Mary's Hospital, Manchester, UK; Department of Obstetrics and Gynaecology, Manchester Academic Health Science Centre, St Mary's Hospital, Central Manchester NHS Foundation Trust, Manchester Academic He
  • O'Connell RL; NHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia.
  • Banerjee S; The Royal Marsden NHS Foundation Trust, London, UK.
  • Mileshkin L; Peter MacCallum Cancer Centre and The Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, VIC, Australia.
  • Sykes P; Dept of Obstetrics and Gynaecology, University of Otago, New Zealand.
  • Beale P; Chris O'Brien Lifehouse, Sydney, NSW, Australia.
  • Fisher A; Queen Elizabeth Hospital, Gateshead, UK.
  • Bonaventura A; School of Medicine & Public Health, University of Newcastle, Australia.
  • Millan D; Queen Elizabeth University Hospital, Glasgow, UK.
  • Nottley S; Royal Hospital for Women/Prince of Wales Hospital and Prince of Wales Clinical School, University of New South Wales, Sydney, Australia.
  • Benson C; The Royal Marsden NHS Foundation Trust, London, UK.
  • Hamilton A; Peter MacCallum Cancer Centre and The Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, VIC, Australia.
  • Sjoquist K; NHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia.
  • Alexander L; Cancer Research UK Clinical Trials Unit, Institute of Cancer Sciences, University of Glasgow, UK.
  • Kelly C; Cancer Research UK Clinical Trials Unit, Institute of Cancer Sciences, University of Glasgow, UK.
  • Carty K; Cancer Research UK Clinical Trials Unit, Institute of Cancer Sciences, University of Glasgow, UK.
  • Divers L; Cancer Research UK Clinical Trials Unit, Institute of Cancer Sciences, University of Glasgow, UK.
  • Bradshaw N; NHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia.
  • Friedlander M; Royal Women's Hospital, Melbourne, VIC, Australia.
Gynecol Oncol ; 163(3): 524-530, 2021 12.
Article en En | MEDLINE | ID: mdl-34625284
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Uterinas / Carcinosarcoma / Anastrozol / Leiomiosarcoma Tipo de estudio: Clinical_trials / Observational_studies Aspecto: Patient_preference Límite: Adult / Aged / Aged80 / Female / Humans / Middle aged Idioma: En Revista: Gynecol Oncol Año: 2021 Tipo del documento: Article Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Uterinas / Carcinosarcoma / Anastrozol / Leiomiosarcoma Tipo de estudio: Clinical_trials / Observational_studies Aspecto: Patient_preference Límite: Adult / Aged / Aged80 / Female / Humans / Middle aged Idioma: En Revista: Gynecol Oncol Año: 2021 Tipo del documento: Article Pais de publicación: Estados Unidos